ArticleFrontiers in immunology2026
Identification and experimental validation of prognostic genes associated with dietary restriction-related signatures in bladder cancer.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bladder cancer (BLCA) is a common urinary tract malignancy with significant global burden, yet the prognostic relevance of dietary restriction-related genes (DRRGs) in BLCA remains unclear. Methods: Prognostic DRRGs in BLCA were identified based on publicly available databases by differential expression analysis, univariate Cox regression analysis, Mendelian randomization (MR) analysis and LASSO regression analysis. A risk model was built and evaluated, after which a nomogram was established and assessed by using the risk score and clinical characteristics. Following this, analysis of functional enrichment, immune infiltration, genetic mutation and drug sensitivity were performed based on the risk model. Importantly, cell annotation and identification of potential key cells were conducted by single-cell RNA sequencing (scRNA-seq) analysis. The expression levels of target DRRGs were examined by qRT-PCR and western blot methods. Cell transfection, Results: Three candidate prognostic DRRGs (RBP7, SREBF1 and ZFP64) were screened. The risk model classified BLCA patients two risk groups, and high-risk patients showed worse survival. The AUC values of this model in the training and validation cohorts were generally within the range of 0.60-0.66, suggesting some but limited discriminatory ability. The risk score, age, T stage, and N stage were identified as independent prognostic factors, and the nomogram constructed from these factors showed moderate predictive performance. The two risk groups differed in signaling pathways, immune cell infiltration, immune checkpoints, mutated genes, immunotherapy-related predictive indicators, and drug sensitivity. scRNA-seq analysis annotated eight cell types, among which T cells showed differential expression of the candidate DRRGs and were identified as a potential key cell type associated with prognostic DRRG expression. Experiments showed that SREBF1 and ZFP64 were over-expressed at mRNA and protein levels in BLCA tissues. Knockdown of SREBF1 or ZFP64 inhibited multiple malignant phenotypes of BLCA cells. Conclusions: This study screened RBP7, SREBF1, and ZFP64 from a previously computationally inferred DR-related gene category as candidate prognostic genes in BLCA and established a risk model with moderate predictive performance, providing clues for further investigation of this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.